Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma
Davide Franceschini(IRCCS Humanitas Research Hospital), Marta Scorsetti(Humanitas University), Fiorenza De Rose, Tiziana Comito(Humanitas University), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Pierina Navarria(IRCCS Humanitas Research Hospital), Ciro Franzese(IRCCS Humanitas Research Hospital), Maria Chiara Tronconi(Ospedale San Carlo), Giuseppe Roberto D’Agostino(Humanitas University), A. Tozzi(Humanitas University)
Cited by 19
Related Papers
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646